ReShape furnishes investor presentation for pending Vyome merger, new ticker HIND

Vyome Holdings, Inc

Filed investor presentation slides on July 15, 2025 in connection with proposed merger with Vyome Therapeutics.
Presentation describes Vyome as a US-India clinical-stage platform focused on immuno-inflammation assets.
Combined company expected to trade on Nasdaq under ticker symbol HIND (pending stockholder and regulatory approvals).
Merger and asset sale subject to stockholder vote; joint proxy statement/prospectus filed June 24, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.